Autolus Therapeutics Ltd (AUTL) - Net Assets
Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) has net assets worth $108.83 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($527.07 Million) and total liabilities ($418.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore AUTL total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $108.83 Million |
| % of Total Assets | 20.65% |
| Annual Growth Rate | 24.01% |
| 5-Year Change | -43.15% |
| 10-Year Change | 24.91% |
| Growth Volatility | 130.51 |
Autolus Therapeutics Ltd - Net Assets Trend (2015–2025)
This chart illustrates how Autolus Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Check AUTL tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Autolus Therapeutics Ltd (2015–2025)
The table below shows the annual net assets of Autolus Therapeutics Ltd from 2015 to 2025. For live valuation and market cap data, see AUTL stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $178.13 Million | -58.32% |
| 2024-12-31 | $427.32 Million | +283.34% |
| 2023-12-31 | $111.47 Million | -62.68% |
| 2022-12-31 | $298.67 Million | -4.67% |
| 2021-12-31 | $313.32 Million | +49.18% |
| 2020-12-31 | $210.03 Million | -17.58% |
| 2019-12-31 | $254.84 Million | +24.23% |
| 2018-12-31 | $205.14 Million | 0.00% |
| 2018-09-30 | $205.14 Million | +43.86% |
| 2017-12-31 | $142.60 Million | +364.70% |
| 2016-12-31 | $30.69 Million | +48.20% |
| 2015-12-31 | $20.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Autolus Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 137742181200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.01% |
| Other Comprehensive Income | $-5.36 Million | -3.01% |
| Other Components | $1.57 Billion | 881.51% |
| Total Equity | $178.13 Million | 100.00% |
Autolus Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Autolus Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Huakong Seg Co Ltd
SHE:000068
|
$385.95 Million |
|
XMax Inc.
NASDAQ:XWIN
|
$385.96 Million |
|
Dare Technology Co Ltd
SHE:000910
|
$386.09 Million |
|
Shandong Meichen Science & Technology Co Ltd
SHE:300237
|
$386.13 Million |
|
Beijing Jingyeda Technology Co Ltd
SHE:003005
|
$385.66 Million |
|
Archer Ltd.
LSE:0RBA
|
$385.60 Million |
|
Maha Energy AB (publ)
ST:MAHA-A
|
$385.54 Million |
|
Valhi Inc
NYSE:VHI
|
$385.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Autolus Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 427,325,000 to 178,129,000, a change of -249,196,000 (-58.3%).
- Net loss of 288,199,915 reduced equity.
- Other comprehensive income increased equity by 23,818,000.
- Other factors increased equity by 15,185,915.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-288.20 Million | -161.79% |
| Other Comprehensive Income | $23.82 Million | +13.37% |
| Other Changes | $15.19 Million | +8.53% |
| Total Change | $- | -58.32% |
Book Value vs Market Value Analysis
This analysis compares Autolus Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.97x to 2.17x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $1.50 | $1.45 | x |
| 2016-12-31 | $2.23 | $1.45 | x |
| 2017-12-31 | $10.35 | $1.45 | x |
| 2018-09-30 | $6.50 | $1.45 | x |
| 2018-12-31 | $6.50 | $1.45 | x |
| 2019-12-31 | $5.92 | $1.45 | x |
| 2020-12-31 | $4.07 | $1.45 | x |
| 2021-12-31 | $4.35 | $1.45 | x |
| 2022-12-31 | $3.14 | $1.45 | x |
| 2023-12-31 | $0.64 | $1.45 | x |
| 2024-12-31 | $1.67 | $1.45 | x |
| 2025-12-31 | $0.67 | $1.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Autolus Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -161.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -381.40%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 3.31x
- Recent ROE (-161.79%) is below the historical average (-61.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -36.05% | -7931.14% | 0.00x | 1.09x | $-9.53 Million |
| 2016 | -40.90% | -1035.48% | 0.04x | 1.11x | $-15.62 Million |
| 2017 | -13.83% | -1165.21% | 0.01x | 1.04x | $-33.99 Million |
| 2018 | -15.17% | -2976.49% | 0.00x | 1.06x | $-51.63 Million |
| 2018 | -15.17% | -2976.49% | 0.00x | 1.06x | $-51.63 Million |
| 2019 | -48.60% | -4258.91% | 0.01x | 1.19x | $-149.33 Million |
| 2020 | -67.65% | -8285.36% | 0.01x | 1.40x | $-163.10 Million |
| 2021 | -45.35% | -9429.06% | 0.00x | 1.29x | $-173.43 Million |
| 2022 | -49.83% | -2402.95% | 0.01x | 1.64x | $-178.71 Million |
| 2023 | -186.93% | -12272.26% | 0.00x | 3.37x | $-219.53 Million |
| 2024 | -51.64% | -2180.45% | 0.01x | 1.83x | $-263.39 Million |
| 2025 | -161.79% | -381.40% | 0.13x | 3.31x | $-306.01 Million |
Industry Comparison
This section compares Autolus Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $77,686,789
- Average return on equity (ROE) among peers: -196.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Autolus Therapeutics Ltd (AUTL) | $108.83 Million | -36.05% | 3.84x | $385.91 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $137.61 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $159.22 Million | 44.71% | 0.38x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $153.84 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $136.85 Million | -50.75% | 0.43x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $290.29K | -1602.16% | 3.15x | $29.90 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $10.96 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $30.68 Million | -84.47% | 0.32x | $3.66 Billion |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more